Skip to main content
. 2021 Jun 18;11:684531. doi: 10.3389/fonc.2021.684531

Figure 4.

Figure 4

The specificity of serum HCP5 in GC and differentiating from gastritis and healthy donors. (A) Detection of serum HCP5 in 19 thyroid cancer patients. (B) Detection of serum HCP5 in 20 colorectal cancer patients. (C) Detection of serum HCP5 in 17 breast cancer patients. (D) The expression levels of HCP5 in gastritis patients (n=21) and healthy donors (n=21). (E) The concentrations of CEA in gastritis patients (n=21) and healthy donors (n=21). (F) The concentrations of CA199 in gastritis patients (n=21) and healthy donors (n=21). *P < 0.05, **P < 0.01, NS means no statistically difference.